Economic Impact and Unmet Needs in ATTR-CM

In this episode titled, ‘Economic Impact and Unmet Needs in ATTR-CM,’ Dr. Alexander outlines the key cost drivers of ATTR-CM from a clinical perspective, noting that patients typically see 4 to 5 physicians before receiving a diagnosis. This prolonged diagnostic journey generates substantial costs through repeated outpatient visits, diagnostic imaging, laboratory testing, and hospitalizations. He emphasizes that the cost burden increases exponentially as the disease advances, drawing a parallel to other forms of cardiomyopathy where frequent heart failure hospitalizations and high readmission rates drive significant healthcare expenditure.

Dr. Haumschild reinforces this point using a multiple myeloma analogy, highlighting that early disease control is essential to reducing downstream costs. Dr. Alexander agrees, noting that patients caught early can maintain stable functional status over time, whereas those already experiencing heart failure hospitalizations face a much higher ongoing care burden, including escalating diuretic needs, arrhythmia procedures, and complications such as renal dysfunction.

The conversation then turns to remaining unmet needs. Dr. Alexander identifies three key gaps: the continued low diagnosis rate of only 20 to 25% of patients with ATTR-CM, health equity disparities that limit access to specialists and specialized testing in lower-resourced communities, and the need for therapies that not only slow but ultimately reverse disease progression. Dr. Haumschild closes by underscoring the importance of treatment durability and specialist-driven awareness as central strategies for improving patient outcomes.

The next episode in this series, ‘Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM,’ features the panelists advancing their conversation on ATTR-CM, focusing on the mechanisms behind TTR stabilizers and silencers, and reviewing the three pivotal Phase III trials for tafamidis, acoramidis, and vutrisiran, each demonstrating strong clinical benefits in cardiovascular outcomes, mortality, and quality of life.